CATTRINI, CARLO
 Distribuzione geografica
Continente #
EU - Europa 3.488
AS - Asia 20
NA - Nord America 1
Totale 3.509
Nazione #
IT - Italia 3.488
CN - Cina 16
SG - Singapore 3
US - Stati Uniti d'America 1
VN - Vietnam 1
Totale 3.509
Città #
Genova 1.557
Genoa 1.280
Rapallo 337
Vado Ligure 312
Beijing 4
Singapore 3
Bordighera 2
Ashburn 1
Ninh Bình 1
Totale 3.497
Nome #
Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome 223
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer 178
Androgen-deprivation therapy is more than palliation in oligometastatic prostate cancer 166
A hnRNP K–AR-related signature reflects progression toward castration-resistant prostate cancer 165
CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials 161
Prognostic variables in localized small cell neuroendocrine carcinoma of the bladder: A population-based study 160
Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: A mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes 155
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer 150
Cisplatin (C)-paclitaxel (P) chemotherapy (CT) regimen with concurrent radiotherapy (RT) in local advanced (LACC) or recurrent (LRCC) cervical cancer: 14 year-results of a phase II study 146
Targeting androgen-independent pathways: new chances for patients with prostate cancer? 142
Bone metastases from prostate cancer: hormonal therapy 138
Genitourinary tumours in the targeted therapies era: New advances in clinical practice and future perspectives 134
Immunotherapy for genitourinary cancer: State of the art and new perspectives 132
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients 131
A large SEER- based study of survival trends in patients with de novo metastatic prostate cancer 119
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study 118
Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes 113
To switch or not to switch? A real-life experience using dexamethasone in combination with abiraterone 113
Lipidomic profiling in patients with metastatic castration-resistant prostate cancer (mCRPC) 110
Reduced dose of cabazitaxel in metastatic castration-resistant prostate cancer: from PROSELICA trial to the real life: A single institution experience 103
Atezolizumab and bladder cancer: facing a complex disease 102
EFFICACY AND SAFETY OF SUNITINIB AND EVEROLIMUS AS FRONTLINE TREATMENT FOR NON-CC-RCC: A POOLED-ANALYSIS FROM RANDOMIZED TRIALS 102
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study 89
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications 89
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 86
Integrative Analysis of Periostin in Primary and Advanced Prostate Cancer 84
Combination therapy in metastatic renal cell carcinoma: Back to the future? 81
Real-world survival improvements in patients with newly diagnosed metastatic prostate cancer treated in the United States 71
null 40
Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty? 39
Totale 3.640
Categoria #
all - tutte 12.907
article - articoli 12.196
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 424
Totale 25.527


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021291 0 0 0 63 38 32 6 32 18 50 23 29
2021/2022344 15 10 16 30 16 40 7 85 25 35 25 40
2022/2023388 28 47 3 37 79 55 0 30 50 7 47 5
2023/2024306 10 63 8 43 10 55 12 8 10 16 11 60
2024/2025830 30 47 26 72 88 75 94 176 16 34 89 83
2025/2026442 169 18 185 70 0 0 0 0 0 0 0 0
Totale 3.640